Sanofi Tries To ‘Bring More Of The Outside In’ For Diversity Efforts
Company Announces New DE&I Board
Executive Summary
The company is focusing first on gender parity as it navigates around tricky legal frameworks on collecting demographic data.
You may also be interested in...
BIO 2022 Notebook: Future Directions For R&D
News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.
BIO 2022 Notebook: Future Directions For R&D
News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.
How Can Pharma Seek To Discuss Gender Diversity?
As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.